BCLSI
XLO icon

Bain Capital Life Sciences Investors’s Xilio Therapeutics XLO Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.36M Hold
664,021
– – 0.38% 19
2026
Q1 		$5.58M Buy
664,021
+137,401
+26% +$1.13M 0.5% 19
2025
Q4 		$4.72M Buy
526,620
+200,419
+61% +$2.11M 0.36% 18
2025
Q3 		$3.85M Hold
326,201
– – 0.26% 17
2025
Q2 		$3.1M Hold
326,201
– – 0.39% 17
2025
Q1 		$3.31M Hold
326,201
– – 0.49% 18
2024
Q4 		$4.36M Hold
326,201
– – 0.51% 20
2024
Q3 		$3.6M Buy
326,201
+55,812
+21% +$685K 0.37% 22
2024
Q2 		$3.59M Buy
270,389
+70,002
+35% +$1.1M 0.39% 21
2024
Q1 		$3.03M Hold
200,387
– – 0.24% 25
2023
Q4 		$1.54M Hold
200,387
– – 0.15% 26
2023
Q3 		$5.92M Hold
200,387
– – 0.66% 26
2023
Q2 		$7.35M Hold
200,387
– – 0.76% 25
2023
Q1 		$8.89M Hold
200,387
– – 1.11% 24
2022
Q4 		$7.55M Hold
200,387
– – 0.84% 26
2022
Q3 		$8.16M Hold
200,387
– – 0.97% 23
2022
Q2 		$8.19M Hold
200,387
– – 0.96% 22
2022
Q1 		$19.8M Hold
200,387
– – 1.93% 14
2021
Q4 		$44.9M Buy
+200,387
New +$47.8M 3.56% 10

Other funds holding XLO

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bain Capital Life Sciences Investors's XLO Position: Q2 2026 in Review

Bain Capital Life Sciences Investors held its Xilio Therapeutics (XLO) position steady in Q2 2026 at 664,021 shares worth $6.36M. The position accounts for 0.38% of the portfolio, ranked #19.

Bain Capital Life Sciences Investors first reported a position in XLO in Q4 2021 and has held it in 19 quarters since. The position peaked at $44.9M in Q4 2021. 27 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Bain Capital Life Sciences Investors held 664,021 shares of Xilio Therapeutics worth $6.36M as of Q2 2026.
  • Bain Capital Life Sciences Investors left its Xilio Therapeutics share count unchanged in Q2 2026.
  • Xilio Therapeutics made up 0.38% of Bain Capital Life Sciences Investors's portfolio in Q2 2026, its #19 holding.
  • Bain Capital Life Sciences Investors first reported a position in Xilio Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Bain Capital Life Sciences Investors's Xilio Therapeutics position peaked at $44.9M in Q4 2021.
  • 27 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.